Immunome Inc. (IMNM) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 25.03 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 24% of 52W Range • RSI-14 at 39.5 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While IMNM currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.44) and Max Pain ($19.20) forces dealer call-delta covering toward $31.56.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Immunome Inc. (IMNM) dropped -2.50% to $18.29, trading at 24% of its 52-week range ($14.64 – $30.06). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
BOTHELL, Wash., October 30, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the Eur
The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpointsIf approved,
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $35 price target.
BOTHELL, Wash., October 26, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presenta
Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48Four presentations build on the previously reported Phase 3 RINGSIDE resultsImmunome, Inc.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -23.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IMNM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IMNM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Immunome Inc. (IMNM) ranks #697 by composite RQD confidence (38/100, grade D-) and #251 by equity capitalization ($2.16B). Within this direct 5-issuer industry benchmark cohort, IMNM leads on earnings valuation at N/A trailing P/E, while XNCR leads on capital efficiency and profitability with -21.3% ROIC and — gross margin. LKFT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with IMNM at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMNM
ACTIVE
Immunome Inc. | D- | 38/100 | — | — | -35.0% | -2.50% | $2.16B | Benchmark Subject |
| XNCR Xencor Inc. | D- | 43/100 | — | — | -21.3% | -2.60% | $2.17B | /xncr-vs-imnm → |
| PVLA Palvella Therapeutics Inc. | D | 46/100 | — | — | -27.9% | +2.79% | $2.18B | /pvla-vs-imnm → |
| LKFT Lakefront Biotherapeutics | C- | 61/100 | — | — | — | +0.78% | $2.13B | /lkft-vs-imnm → |
| MRVI Maravai LifeSciences Holdings Inc. (Class A) | D- | 36/100 | — | 18.3% | -35.0% | -0.47% | $2.20B | /mrvi-vs-imnm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immunome Inc. (IMNM) reported GAAP revenue of $6.9M (-23.2% vs. FY2024 revenue of $9.0M , and -50.5% cumulative change since FY2023) , GAAP net income of -$212.4M, operating cash flow of -$190.9M, and free cash flow of -$200.6M (-70.1% YoY). On the balance sheet, IMNM closed FY2025 with $683.2M in total assets against $0 in total debt (Altman Z-Score: 25.03, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.9M | -$212.4M | -$190.9M | -$200.6M | $683.2M | — |
| FY2024 (FY) | 2024-12-31 | $9.0M | -$293.0M | -$110.8M | -$118.0M | $240.2M | — |
| FY2023 (FY) | 2023-12-31 | $14.0M | -$106.8M | -$7.6M | -$7.6M | — | — |
As of 2026-11-01, Immunome Inc. (NASDAQ: IMNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $18.29 (-2.50% 1D, market cap $2.16B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMNM ranks #697 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XNCR (Xencor Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -21.3%, cap $2.17B) and PVLA (Palvella Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -27.9%, cap $2.18B). Among the 5-stock peer group, IMNM leads on earnings multiple (N/A) while XNCR leads on capital efficiency (-21.3% ROIC).
Per IMNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001472012), Immunome Inc. generated $6.9M in revenue (-23.2% YoY), -$212.4M in net income, and -$200.6M in free cash flow against $683.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
IMNM last traded at $18.29 (-2.50% on volume of 877,933 shares), positioning the stock -18.49% below its 50-day simple moving average ($22.44) and -18.67% below its 200-day simple moving average ($22.49). Across its 52-week range of $14.64 to $30.06, IMNM sits at the 23.7% percentile with a 14-day RSI of 39.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($16.15 to $20.43).
Why IMNM Stock dropped -2.50% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.